STOCK TITAN

HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on May 9, 2024, to discuss its first-quarter results, regulatory updates, ongoing initiatives, and 2024 milestones. CEO Branislav Vajdic, President Robert Eno, and Consulting CFO Richard Brounstein will lead the call. Investors can access the webcast or call in using the provided details.
HeartBeam, Inc. (NASDAQ: BEAT) ospiterà una teleconferenza il 9 maggio 2024 per discutere i risultati del primo trimestre, aggiornamenti normativi, iniziative in corso e obiettivi per il 2024. Il CEO Branislav Vajdic, il Presidente Robert Eno e il CFO consulente Richard Brounstein guideranno la chiamata. Gli investitori possono accedere alla webcast o telefonare utilizzando i dettagli forniti.
HeartBeam, Inc. (NASDAQ: BEAT) realizará una llamada de conferencia el 9 de mayo de 2024 para discutir sus resultados del primer trimestre, actualizaciones regulatorias, iniciativas en curso y metas para 2024. El CEO Branislav Vajdic, el Presidente Robert Eno y el CFO consultor Richard Brounstein liderarán la llamada. Los inversores pueden acceder a la transmisión web o llamar utilizando los detalles proporcionados.
HeartBeam, Inc. (NASDAQ: BEAT)는 2024년 5월 9일에 1분기 실적, 규제 업데이트, 진행 중인 이니셔티브 및 2024년도 주요 사항에 대해 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다. CEO 브라니슬라브 바이딕, 사장 로버트 에노, 컨설팅 CFO 리처드 브라운스타인이 이번 콜을 이끌 예정입니다. 투자자는 제공된 세부 정보를 사용하여 웹캐스팅에 접속하거나 전화로 참여할 수 있습니다.
HeartBeam, Inc. (NASDAQ: BEAT) organisera une téléconférence le 9 mai 2024 pour discuter des résultats du premier trimestre, des mises à jour réglementaires, des initiatives en cours et des objectifs pour 2024. Le PDG Branislav Vajdic, le Président Robert Eno et le CFO consultant Richard Brounstein dirigeront l'appel. Les investisseurs peuvent accéder à la webdiffusion ou appeler en utilisant les détails fournis.
HeartBeam, Inc. (NASDAQ: BEAT) veranstaltet am 9. Mai 2024 eine Telefonkonferenz, um die Ergebnisse des ersten Quartals, regulatorische Updates, laufende Initiativen und Meilensteine für das Jahr 2024 zu besprechen. CEO Branislav Vajdic, Präsident Robert Eno und beratender CFO Richard Brounstein werden die Konferenz leiten. Investoren können über die bereitgestellten Daten auf den Webcast zugreifen oder sich telefonisch einwählen.
Positive
  • None.
Negative
  • None.

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Thursday May 9, 2024 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call.

HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, and Consulting CFO Richard Brounstein will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:

Thursday May 9, 2024

Time:

4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Dial-in:

1-844-826-3035

International Dial-in:

1-412-317-5195

Conference Code:

10188115

Webcast:

https://viavid.webcasts.com/starthere.jsp?ei=1666005&tp_key=54ba5ed4e5

A telephone replay will be available approximately three hours after the call and will run through August 9, 2024, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10188115. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the company’s investor relations section here.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that is dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (VECG) technology collects 3D signals of the heart’s electrical activity and converts them into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining how cardiac health is managed in the future. For additional information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contact:

Chris Tyson

Executive Vice President

MZ North America

Direct: 949-491-8235

BEAT@mzgroup.us

www.mzgroup.us

Media Contact:

media@heartbeam.com

Source: HeartBeam, Inc.

FAQ

When will HeartBeam host the conference call to discuss its first-quarter results?

HeartBeam will host the conference call on May 9, 2024, at 4:30 p.m. Eastern time.

Who will be leading the conference call for HeartBeam?

The conference call will be led by HeartBeam CEO Branislav Vajdic, President Robert Eno, and Consulting CFO Richard Brounstein.

How can investors access the call?

Investors can access the call through the webcast or by dialing 1-844-826-3035 (U.S.) or 1-412-317-5195 (International) using the conference code: 10188115.

When will the telephone replay of the call be available?

The telephone replay of the call will be available approximately three hours after the call and will run through August 9, 2024.

Heartbeam, Inc.

NASDAQ:BEAT

BEAT Rankings

BEAT Latest News

BEAT Stock Data

53.05M
19.29M
28.17%
8.8%
0.61%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA

About BEAT

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.